FDA Regulation of Regenerative Medicine Products

What this means

In the United States, “regenerative medicine” is a marketing umbrella, not one FDA bucket. Regulation follows what the product is, how it is processed, what it is combined with, and what the clinic claims it will do. A vial can be a drug, a biologic, a device, a human cell or tissue product (HCT/P), or more than one of those at once.

Some HCT/Ps may be regulated solely under section 361 of the Public Health Service Act if they meet every criterion in 21 CFR 1271.10. Those criteria include minimal manipulation and homologous use—the same basic function in the recipient as in the donor. A tissue used as a structural covering can be a different regulatory object than the same tissue ground up and injected to “treat arthritis.”

If any 361 criterion fails, and no narrow exception applies, the product is generally regulated as a section 351 biologic or as a drug. That path usually requires an investigational new drug application (IND) before clinical research and an approved biologics license (BLA) before marketing. FDA warning letters to clinics repeatedly apply this analysis to umbilical-cord, amniotic, and similar injectables sold for joints, nerves, or systemic disease.

Patients meet this framework as advertising. “Registered,” “compliant,” “autologous,” and “same-day” are not synonyms for licensed. FDA consumer pages exist because people have been harmed by unapproved products sold as cures. Understanding 351 versus 361 is how you decode the brochure.

What the evidence shows

FDA’s public position is specific. Approved stem-cell products in the U.S. are, with limited exceptions described on FDA pages, blood-forming cells from cord blood for hematopoietic disorders. They are not approved for autism, macular degeneration, chronic pain, fatigue, orthopedic conditions, or aging. FDA has received reports of infection, blindness, and tumor formation after unapproved regenerative injections.

Exosome products are not FDA-approved as treatments. Stromal vascular fraction from fat, Wharton’s jelly, and amniotic fluid marketed to treat disease generally fall on the 351 side when intended use is not homologous. Warning letters walk through homologous-use failure: a cord’s basic function is not to treat Parkinson’s disease or knee pain.

Device clearance is a separate fact. A centrifuge or processing kit can be cleared as equipment. That clearance does not approve the output for arthritis. ClinicalTrials.gov listing is also separate. A listing is not a license and does not prove a study is well designed or legally conducted under an IND.

ISSCR’s patient guide makes the same practical point in non-legal language: distinguish approved care, legitimate trials, and marketed unproven treatments. Unproven clinic products can cause physical and financial harm and can delay indicated standard care. Society guidance and FDA alerts converge even though they are written for different audiences.

Common myths

Myth: “If it comes from my own body, FDA is not involved.” Autologous products can still be drugs or biologics when processing or intended use crosses the line. Same-surgical-procedure language is a narrow exception, not a slogan. Timing alone does not create 361 status.

Myth: “FDA registered means FDA approved.” Registration tells FDA a firm exists. It is not a review of safety or effectiveness. Clinics often point to a registration number the way a restaurant points to a business license. That is not a menu-item approval.

Myth: “Homologous use means the cells are natural so they belong in a joint.” Homologous use is a regulatory definition about basic function, not a wellness compliment. Injecting birth tissue to treat arthritis is the example FDA letters keep rejecting.

Myth: “A trial listing or IRB stamp means I am getting approved therapy.” You may be a research subject, a cash customer, or both. Ask whether an IND is in effect, what happens if you are harmed, and whether you can get the same diagnosis treated with standard care instead. ISSCR materials encourage a second opinion from a specialist in the disease—not only from the selling clinic.

How clinics use it

Legitimate programs use approved cellular products for labeled indications, or they run IND trials with consent, eligibility, and monitoring. Orthopedic groups that offer PRP are usually using an autologous blood prep with a device; that is a different conversation from a donor “stem-cell” vial. They should still avoid claiming FDA-approved cartilage regeneration.

Cash regenerative and longevity clinics often blur the vocabulary. The same visit may offer cord tissue for knees, exosomes for fatigue, and a slide deck about 361 compliance. Marketing may show a white-coat laboratory and a cell-count graph. Those images do not identify the legal pathway. Ask for the product name, manufacturer, lot, intended use, and whether the clinic claims 361 status or 351/IND status.

Some clinics import patients for “stem-cell tourism” and describe U.S. rules as optional overseas. Harm still follows the patient home. FDA cannot make a foreign vial into an approved U.S. product because the brochure was persuasive. Follow-up for infection is your local emergency department, not the airport clinic.

State medical boards regulate clinicians. They do not replace federal product law. A licensed physician can still administer an unapproved biologic illegally. Licensure is necessary and not sufficient.

Practical takeaway

Start with the indication and the exact product. If the clinic cannot name both, stop. Search FDA’s approved cellular and gene-therapy list for that product and indication. If it is absent, ask whether there is an IND and a real protocol—or whether you are being sold an unapproved 351 product as if it were a 361 tissue.

Treat these phrases as incomplete: registered, cleared equipment, autologous, homologous, minimally manipulated, listed on ClinicalTrials.gov. Each can be true and still leave you with an unlicensed biologic. FDA consumer alerts and warning letters are written in that gap.

Prefer standard care for the diagnosis—physical therapy for tendinopathy, exercise and indicated surgery for knee OA, licensed neurology for neurologic disease—before any unapproved vial. ISSCR’s guide is built for that sequence. Unproven injections are not a parallel healthcare system.

If you proceed in a trial, get the IND number, consent, costs, and an independent second opinion in writing. Report harms through MedWatch. Regulation exists because cells and tissues can infect, mislead, and delay care. Your job as a patient is to ask which statute the clinic thinks it is using—and to walk if the answer is a slogan.